[go: up one dir, main page]

TW200603792A - Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors - Google Patents

Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors

Info

Publication number
TW200603792A
TW200603792A TW094110864A TW94110864A TW200603792A TW 200603792 A TW200603792 A TW 200603792A TW 094110864 A TW094110864 A TW 094110864A TW 94110864 A TW94110864 A TW 94110864A TW 200603792 A TW200603792 A TW 200603792A
Authority
TW
Taiwan
Prior art keywords
psoriasis
cyclooxygenase
treatment
monotherapy
selective inhibitors
Prior art date
Application number
TW094110864A
Other languages
Chinese (zh)
Inventor
Diane T Stephenson
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200603792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TW200603792A publication Critical patent/TW200603792A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compositions and methods for treating psoriasis in a subject. More particularly, the invention provides a therapy for the treatment of psoriasis comprising administering to a subject a cyclooxygenase-2 selective inhibitor.
TW094110864A 2004-04-23 2005-04-06 Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors TW200603792A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56501804P 2004-04-23 2004-04-23

Publications (1)

Publication Number Publication Date
TW200603792A true TW200603792A (en) 2006-02-01

Family

ID=35241424

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094110864A TW200603792A (en) 2004-04-23 2005-04-06 Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors

Country Status (2)

Country Link
TW (1) TW200603792A (en)
WO (1) WO2005105099A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582942T3 (en) 2004-10-08 2016-09-16 Forward Pharma A/S Pharmaceutical controlled release compositions comprising a fumaric acid ester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
RU2690188C2 (en) * 2017-05-26 2019-05-31 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" New multitarget preparation for treating diseases in mammals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510816A (en) * 1995-10-17 2000-08-22 ジー．ディー．サール アンド カンパニー Method for detecting cyclooxygenase-2
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES
DE60016047T2 (en) * 2000-01-03 2005-11-03 Pharmacia Corp., Chicago DIHYDROBENZOPYRANE, DIHYDROBENZOTHIOPYRANE AND TETRAHYDROCHINOLINE FOR THE TREATMENT OF COX-2-DEPENDENT DISEASES

Also Published As

Publication number Publication date
WO2005105099A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
MY169308A (en) Treatment of tnf? related disorders
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
NO20083202L (en) ANG2 and VEFG inhibitor combinations
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MXPA05010476A (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
EA200602241A1 (en) SUBSTITUTED INDASOLES, COMPOSITIONS CONTAINING INDICATED INDASOLES, METHOD OF THEIR RECEIVING AND APPLICATION
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2007058990A3 (en) Therapy using cytokine inhibitors
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
MX2009005114A (en) Use of gabapentin and pregabalin prodrugs for treating tinnitus.
EA200800755A1 (en) IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS
MX2010002667A (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors.
TW200507840A (en) Method of treating multiple myeloma
WO2007130501A3 (en) Combination therapy for treatment of cancer
EA200901062A1 (en) USING INHIBITORS OF SOLUBLE EPOXYDHYDROLASE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND RELEVANT DISORDERS
EA200800766A1 (en) PI3K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS